Phase 3 Parkinson's Disease Trial, Recruiting NCT07174310 Sponsor: Hoffmann-La Roche Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 3 Parkinson's Disease Trial, Recruiting

NCT07174310
Recruiting Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People whose body weight is between 40 and 110 kilograms (about 88 to 242 pounds) and whose body mass index (a measure of body weight relative to height) falls between 18 and 34
  • People who have been diagnosed with idiopathic Parkinson's disease (Parkinson's disease with no known cause) based on recognised Movement Disorder Society guidelines
  • People who have been treated with a single Parkinson's disease medication on its own (not a combination of medications)
  • People whose movement complication score (a specific medical rating called MDS-UPDRS Part IV) is zero at the time of screening and before being assigned to a treatment group
  • People whose Parkinson's disease stage, as measured by the Hoehn and Yahr scale while off medication, is Stage 1 or 2 (indicating earlier-stage disease) at screening and before being assigned to a treatment group
  • People who agree to follow the contraception requirements set out by the trial for its duration

Who may not be able to join:

  • People who are pregnant, breastfeeding, or planning to become pregnant during the trial or within the period when contraception is required
  • People whose medical history suggests a type of Parkinsonism other than idiopathic Parkinson's disease
  • People who have been diagnosed with a significant neurological (brain or nervous system) condition other than Parkinson's disease
  • People who have ongoing high blood pressure that is not well controlled

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Clinical Trials, Hoffmann-La Roche

Phone: 888-662-6728 (U.S. and Canada)

Australian sites

Southern Neurology, Kogarah, New South Wales
Westmead Hospital, Westmead, New South Wales
Monash Health, Clayton, Victoria
Royal Melbourne Hospital, Parkville, Victoria
The Alfred Hospital, Prahan, Victoria
Perron Institute for Neurological and Translational Science, Nedlands, Western Australia

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
24 November 2025
Est. completion
30 June 2029

Where this trial is recruiting

🇦🇺 Australia 🇦🇹 Austria 🇧🇷 Brazil 🇨🇦 Canada 🇨🇳 China 🇩🇰 Denmark 🇫🇷 France 🇩🇪 Germany 🇮🇹 Italy 🇲🇽 Mexico 🇵🇱 Poland 🇵🇹 Portugal 🇰🇷 South Korea 🇪🇸 Spain 🇹🇼 Taiwan 🇬🇧 United Kingdom 🇺🇸 United States

6 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Time to Confirmed Motor Progression Event on Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov